Boston Scientific Co. (NYSE:BSX) Shares Purchased by ProShare Advisors LLC

ProShare Advisors LLC boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 8.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 216,039 shares of the medical equipment provider’s stock after acquiring an additional 16,430 shares during the period. ProShare Advisors LLC’s holdings in Boston Scientific were worth $16,637,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of BSX. Putnam Investments LLC grew its stake in shares of Boston Scientific by 110.5% during the fourth quarter. Putnam Investments LLC now owns 13,067,570 shares of the medical equipment provider’s stock worth $755,436,000 after purchasing an additional 6,859,280 shares in the last quarter. Capital World Investors increased its holdings in shares of Boston Scientific by 236.1% in the 4th quarter. Capital World Investors now owns 9,419,829 shares of the medical equipment provider’s stock valued at $544,560,000 after acquiring an additional 6,617,360 shares during the last quarter. Capital Research Global Investors acquired a new stake in shares of Boston Scientific during the 1st quarter worth about $182,897,000. Vanguard Group Inc. lifted its stake in Boston Scientific by 1.6% during the first quarter. Vanguard Group Inc. now owns 127,437,884 shares of the medical equipment provider’s stock worth $8,728,221,000 after purchasing an additional 1,988,082 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado boosted its holdings in Boston Scientific by 11,484.5% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 1,705,468 shares of the medical equipment provider’s stock valued at $98,593,000 after purchasing an additional 1,690,746 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BSX. Robert W. Baird boosted their price objective on shares of Boston Scientific from $90.00 to $91.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. BTIG Research upped their price objective on shares of Boston Scientific from $80.00 to $84.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Needham & Company LLC lifted their target price on Boston Scientific from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Canaccord Genuity Group boosted their target price on Boston Scientific from $83.00 to $88.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Finally, Evercore ISI raised their price target on Boston Scientific from $78.00 to $81.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 2nd. Three research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $86.65.

Boston Scientific Trading Up 0.1 %

NYSE BSX opened at $84.00 on Tuesday. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $123.24 billion, a P/E ratio of 70.59, a P/E/G ratio of 2.75 and a beta of 0.79. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $84.89. The firm has a 50-day moving average price of $78.84 and a 200 day moving average price of $74.84.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, beating the consensus estimate of $0.58 by $0.04. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The business had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. During the same period last year, the firm earned $0.53 EPS. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. Equities research analysts expect that Boston Scientific Co. will post 2.4 EPS for the current year.

Insider Activity

In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $77.30, for a total transaction of $539,785.90. Following the sale, the executive vice president now owns 42,908 shares of the company’s stock, valued at $3,316,788.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 20,949 shares of company stock worth $1,627,877 in the last 90 days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.